Investigating the Neuroprotective Effect of Copper Oxide Nanoparticles in Reducing Glutamate-Induced Toxicity in PC12 Cells: Implications for the Treatment of Neurological Diseases
Authors
-
Mohsen Zhaleh
- Department of Anatomy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
https://orcid.org/0000-0003-0623-1689
-
Seyedeh Haniyeh Mortazavi
- Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
https://orcid.org/0000-0002-9457-9505
-
Ali Ghanbari
- Department of Anatomy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
https://orcid.org/0000-0002-8656-1639
-
Iraj Rashidi
- Department of Anatomy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
https://orcid.org/0000-0003-3516-1464
DOI:
https://doi.org/10.22100/jkh.v20i1.3435Keywords:
Copper oxide nanoparticles, , Glutamate toxicity, Oxidative stress, PC12 cells, Neurological diseasesAbstract
Introduction: Neurological disorders are among the most challenging central nervous system conditions, often associated with increased oxidative stress and cell death. Plant-based nanoparticles may offer a novel approach to mitigate these effects. To evaluate the antioxidant and neuroprotective effects of copper oxide nanoparticles (CuONPs) synthesized using Scrophularia striata extract against glutamate-induced toxicity in PC12 cells.
Methods: CuONPs were synthesized via green synthesis using plant extract and characterized using XRD, SEM, TEM, and UV-vis. PC12 cells were exposed to glutamate and treated with CuONPs. Oxidative stress markers (ROS, MDA, SOD, CAT) and DNA damage were assessed.
Results: CuONP treatment significantly reduced ROS and MDA levels and enhanced the activity of antioxidant enzymes SOD and CAT. DNA damage was also markedly reduced compared to the glutamate-only group.
Conclusion: CuONPs synthesized with Scrophularia striata possess strong antioxidant and neuroprotective properties and show promise as a potential therapeutic agent for neurodegenerative disorders.
References
Engin AB, Engin A. Nanoparticles and neurotoxicity: dual response of glutamatergic receptors. Prog Brain Res 2019;245:93-115. doi:10.1016/bs.pbr.2019.07.003
Magdaleno Roman JY, Chapa González C. Glutamate and excitotoxicity in central nervous system disorders: ionotropic glutamate receptors as a target for neuroprotection. Neuroprotection 2024;2:137-50.
Lobine D, Sadeer N, Jugreet S, et al. Potential of medicinal plants as neuroprotective and therapeutic properties against amyloid-β-related toxicity, and glutamate-induced excitotoxicity in human neural cells. Curr Neuropharmacol 2021;19:1416-41. doi:10.2174/1570159X19666210412093756
Moghadam ZE, Hamidi S, Azarfarin M, et al. Emerging promise of green synthesized metallic nanoparticles for the management of neurological disorders. Curr Pharm Des 2024;30.
Chen SQ, Wang ZS, Ma YX, et al. Neuroprotective effects and mechanisms of tea bioactive components in neurodegenerative diseases. Molecules 2018;23:512. doi:10.3390/molecules23030512
Ait Hamdan Y, Elouali S, Maloui AB, et al. Chitosan and its derivatives as potential neuroprotective agents for the treatment of Parkinson’s disease. In: Experimental and Clinical Evidence of the Neuropathology of Parkinson’s Disease. IGI Global 2023:253-74.
Jiang Y, Tang X, Deng P, et al. The neuroprotective role of fisetin in different neurological diseases: a systematic review. Mol Neurobiol 2023;60:6383-94. doi:10.1007/s12035-023-03481-x
Bhattacharya T, Soares GA, Chopra H, et al. Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders. Materials 2022;15:804. doi:10.3390/ma15030804
Palaniyappan R, Arthanari S, Subramanian M, et al. Nanotechnology-driven approaches in overcoming drug delivery challenges for neurodegenerative diseases. Indian J Pharm Educ Res 2024;58:S1185-200.
Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007;145:1233-48. doi:10.1016/j.neuroscience.2007.01.004
Uttara B, Singh AV, Zamboni P, et al. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009;7:65-74. doi:10.2174/157015909787602823
Wang Y, Cai R, Chen C. The nano–bio interactions of nanomedicines: understanding the biochemical driving forces and redox reactions. Acc Chem Res 2019;52:1507-18. doi:10.1021/acs.accounts.9b00126
Lee KH, Cha M, Lee BH. Neuroprotective effect of antioxidants in the brain. Int J Mol Sci 2020;21:7152. doi:10.3390/ijms21197152
Afzal O, Altamimi AS, Nadeem MS, et al. Nanoparticles in drug delivery: from history to therapeutic applications. Nanomaterials 2022;12:4494. doi:10.3390/nano12244494
Janrao C, Khopade S, Bavaskar A, et al. Recent advances of polymer-based nanosystems in cancer management. J Biomater Sci Polym Ed 2023;34:1274-335. doi:10.1080/09205063.2023.2199412
Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003;53:S26-38. doi:10.1002/ana.10483
Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature 2004;430:631-9. doi:10.1038/nature02621
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
